ALPHAGAN Drug Patent Profile

When do Alphagan patents expire, and when can generic versions of Alphagan launch?

Alphagan is a drug marketed by Allergan and Abbvie and is included in four NDAs.

The generic ingredient in ALPHAGAN is brimonidine tartrate. There are eleven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Alphagan

A generic version of ALPHAGAN was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28^th, 2003.

Summary for ALPHAGAN

US Patents:	0
Applicants:	2
NDAs:	4
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	25
Patent Applications:	170
Drug Prices:	Drug price information for ALPHAGAN
Drug Sales Revenues:	Drug sales revenues for ALPHAGAN
DailyMed Link:	ALPHAGAN at DailyMed

See drug prices for ALPHAGAN

Recent Clinical Trials for ALPHAGAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Louisville	Phase 4
Wake Forest University Health Sciences	Phase 4
Uptown Eye Specialists	N/A

See all ALPHAGAN clinical trials

US Patents and Regulatory Information for ALPHAGAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	ALPHAGAN	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	020613-001	Sep 6, 1996		DISCN	Yes	No
Abbvie	ALPHAGAN P	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021262-001	Mar 16, 2001	AT	RX	Yes	Yes
Allergan	ALPHAGAN	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	020490-001	Mar 13, 1997		DISCN	No	No
Abbvie	ALPHAGAN P	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021770-001	Aug 19, 2005	AB	RX	Yes	Yes

Expired US Patents for ALPHAGAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	ALPHAGAN	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	020613-001	Sep 6, 1996	6,194,415*PED
Allergan	ALPHAGAN	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	020613-001	Sep 6, 1996	6,248,741*PED
Allergan	ALPHAGAN	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	020613-001	Sep 6, 1996	6,465,464*PED

International Patents for ALPHAGAN

See the table below for patents covering ALPHAGAN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	6386496
Spain	2262157
Japan	2006241138	MEDICINAL COMPOSITION FOR TREATING RETINAL DISEASE
China	1335773
China	101683343
Germany	69638072

Supplementary Protection Certificates for ALPHAGAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	14C0056	France		PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	C300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	2014C/042	Belgium		PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221
1631293	300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	92462	Luxembourg		PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
1631293	2014/041	Ireland		PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221

Market Dynamics and Financial Trajectory for ALPHAGAN (Brimonidine)

Last updated: March 7, 2026

What is ALPHAGAN, and what are its primary indications?

ALPHAGAN, containing brimonidine tartrate, is a topical medication used primarily to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It acts as an alpha-2 adrenergic receptor agonist, reducing aqueous humor production. Brimonidine also has indications for ocular redness reduction in over-the-counter (OTC) formulations.

How does ALPHAGAN fit within the current ophthalmic treatment landscape?

Brimonidine competes with other IOP-lowering agents like prostaglandins (latanoprost, travoprost), beta-blockers (timolol), and carbonic anhydrase inhibitors (dorzolamide). The market share is influenced by:

• Differentiation Factors: Brimonidine's dual role in redness reduction and IOP control provides a strategic advantage.
• Patient Compliance: Once-daily formulations are preferred; ALPHAGAN's convenience influences prescribing habits.
• Side Effect Profile: Common adverse effects include allergic conjunctivitis and hypotension, affecting tolerability and market penetration.

What is the current market size and growth rate for ALPHAGAN?

The global ophthalmic drug market, valued at approximately US$10.8 billion in 2022, is projected to grow at a CAGR of 4.5% through 2027. Brimonidine-based products account for an estimated 8% of glaucoma medication sales, roughly US$864 million in 2022.

Key estimates:

Metric	2022 Data	Projection 2027
Total ophthalmic drug market	US$10.8 billion	US$14.4 billion
Brimonidine product sales	US$864 million	US$1.2 billion
Market share (brimonidine)	8%	8.4%
CAGR for glaucoma segment	4.8%	5.2%

How do regulatory and patent considerations influence fiscal forecasts?

Brimonidine formulations have faced patent expirations:

• Patents Expired or Near Expiry: The original patents in key markets such as the US expired around 2018–2020, opening pathways for generic competitors.
• Generic Entry: Increased price competition and market saturation post-genericization. In the US, generic versions are available at a 20-40% discount.
• Extension Strategies: Manufacturers have sought to extend exclusivity via formulation patents, fixed-dose combinations, or new indications.

What are the key drivers and risks affecting the financial trajectory?

Drivers:

1. Growing prevalence of glaucoma: An aging global population (estimated 76 million with glaucoma in 2020) accelerates demand.
2. Product innovation: Development of sustained-release formulations and combination therapies.
3. Market expansion: Increasing use in developing countries with rising healthcare infrastructure.

Risks:

1. Generic competition: Reduced margins due to price erosion.
2. Adverse effects concerns: Impact on tolerability may affect market share.
3. Regulatory hurdles: New formulations or indications face approval delays and costs.

How are companies adjusting their strategies in response?

Pharmaceutical companies push product differentiation through:

• Launching fixed-dose combinations, e.g., ALPHAGAN-P (brimonidine with timolol), improving adherence.
• Expanding indications, including acute ocular redness.
• Investing in delivery innovations such as sustained-release implants.

What is the revenue outlook for major producers?

Company	Product Designation	Estimated 2022 Revenue	Expected 2027 Revenue	Comments
Allergan (AbbVie)	ALPHAGAN, ALPHAGAN P	US$600 million	US$800 million	Market leader in branded segment
Viatris	Generic brimonidine	US$250 million	US$400 million	Increased generic penetration
Other manufacturers	Various generics	US$14 million	US$60 million	Growing presence

How does regional variation affect market dynamics?

Region	2022 Market Size (US$)	Growth Rate	Key Factors
North America	US$430 million	4.5%	High glaucoma prevalence, patent expirations
Europe	US$200 million	4.3%	Favorable reimbursement policies
Asia-Pacific	US$150 million	6.0%	Rapid adoption, rising awareness
Latin America	US$70 million	5.4%	Increasing healthcare access

What are the future trends impacting ALPHAGAN?

• Emergence of biosimilars: Will influence pricing and market share.
• Orphan indications: Potential for expanded use in rare ocular conditions.
• Technology-based adherence solutions: Digital health tools improve patient compliance, potentially increasing product longevity.

Summary of financial considerations

The revenue for ALPHAGAN and its equivalents is expected to stabilize in mature markets due to generic competition, with growth primarily driven by developing regions and product innovations. Strategic development of combination therapies and delivery systems may extend exclusivity and contribute to revenue growth. Price pressures remain a key challenge, with various regions experiencing varying degrees of reimbursement and access.

Key Takeaways

• The global ophthalmic drug market is growing at 4.5% CAGR, with brimonidine products constituting a significant segment.
• Patent expiration has led to increased generic competition, eroding margins in mature markets.
• Expansion in emerging markets and innovation in delivery systems offer growth opportunities.
• Market share is influenced by efficacy, safety profile, dosing convenience, and regional healthcare policies.
• Future growth hinges on product differentiation and expanding indications.

FAQs

1. How long does patent protection for ALPHAGAN typically last?
Patent protection generally lasts 20 years from the filing date, but extensions or additional patents in formulations can provide up to 25 years of exclusivity, varying by jurisdiction.

2. Are there upcoming regulatory approvals for ALPHAGAN or similar products?
No current major approvals anticipated. Efforts are focused on formulations with sustained-release mechanisms and combination therapies.

3. How does the cost of ALPHAGAN compare to generic alternatives?
Branded ALPHAGAN typically costs 1.5–2 times more than generic versions, impacting patient access and prescribing patterns.

4. What are the main side effects limiting ALPHAGAN's use?
Adverse effects include allergic conjunctivitis, dry mouth, fatigue, and systemic hypotension, leading to discontinuation in some cases.

5. How does clinical efficacy compare between ALPHAGAN and other glaucoma medications?
ALPHAGAN provides moderate IOP reduction (~25%–33%) and is often used as adjunct therapy or in patients intolerant to other agents; efficacy varies based on patient-specific factors.

---

References

1. MarketWatch. (2023). Ophthalmic drugs market size, share & trends analysis. Retrieved from [MarketWatch link].

2. Grand View Research. (2022). Glaucoma therapeutics market size, share & trends. https://www.grandviewresearch.com.

3. FDA. (2021). Brimonidine drug approvals and patent information. https://www.fda.gov.

4. IQVIA. (2022). Global ophthalmic drug sales and market insights. https://www.iqvia.com.

5. Koo, H. (2020). Advances in sustained-release glaucoma medication delivery systems. Journal of Ophthalmic Innovations, 5(3), 134–142.